Carregant...
PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
Targeting mutant BRAF in patients with melanomas harboring this oncogene has been highly successful as a first-line treatment, but other mutations may affect its efficacy and alter the route of acquired resistance resulting in recurrence and poor prognosis. As an evolving strategy, melanoma treatmen...
Guardat en:
| Publicat a: | NPJ Precis Oncol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8289936/ https://ncbi.nlm.nih.gov/pubmed/34282258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00207-x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|